Gyre Therapeutics, Inc. (GYRE) vs Lexicon Pharmaceuticals, Inc. (LXRX)
A side-by-side comparison of Gyre Therapeutics, Inc. and Lexicon Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
GYRE
Gyre Therapeutics, Inc.
$7.16HealthcareDelayed quote: Oct 6, 2026, 11:05 AM EDT
LXRX
Lexicon Pharmaceuticals, Inc.
$1.75HealthcareDelayed quote: Oct 6, 2026, 11:05 AM EDT
Total return — GYRE vs LXRX
growth of $100 · dividends reinvested · last 10yGYRE -79.5% (-14.6%/yr)LXRX -90.4% (-20.9%/yr)GYRE compounded faster over this window
GYRE LXRX
GYRE vs LXRX: by the numbers
- •GYRE is the larger company ($798M vs $778M market cap).
- •Both run net losses; GYRE's is the smaller (-14.52% vs -147.38% net margin).
- •GYRE grew revenue faster over the past five years (84.92% vs 42.36% CAGR).
Metrics side by side
Valuation
| Metric | GYRE | LXRX |
|---|---|---|
| P/S ratio | 6.68 | 18.76 |
| P/B ratio | 7.39 | 4.46 |
Profitability
| Metric | GYRE | LXRX |
|---|---|---|
| Gross margin | 94.30% | 98.85% |
| Operating margin | 9.86% | -98.21% |
| Net margin | -14.52% | -147.38% |
| ROE | -13.30% | -35.02% |
| ROIC | -9.77% | -23.16% |
Growth (annualized)
| Metric | GYRE | LXRX |
|---|---|---|
| Revenue CAGR (5Y) | 84.92% | 42.36% |
| Total return CAGR (5Y) | -0.34% | -18.54% |
Frequently asked
- Which has grown faster, GYRE or LXRX?
- Over the past five years, GYRE grew revenue faster — GYRE at a 84.92% CAGR versus LXRX at 42.36%.
- How have GYRE and LXRX total returns compared?
- Over the past 10 years, GYRE delivered -14.92% and LXRX delivered -21.03% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Gyre Therapeutics ROELexicon Pharmaceuticals ROEGyre Therapeutics operating marginLexicon Pharmaceuticals operating marginGyre Therapeutics revenue growthLexicon Pharmaceuticals revenue growthGyre Therapeutics free cash flowLexicon Pharmaceuticals free cash flow
Gyre Therapeutics & Lexicon Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.